Please assess the completion status of the following clinical trial:

Trial Title: Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All children and adolescents (5-18 years) with asthma in Tayside (Scotland) known:~* To carry the Arg/Arg-16 genotype and~* Currently on inhaled steroids and~* Inhaled bronchodilators according to need will be telephoned or contacted through home visits to establish if they have had:~  * Any school absences from asthma or~ * Out-of-hours visits to GP/hospital visits or admissions due to asthma over the previous 12 months.~Exclusion Criteria:~* The presence of serious respiratory or multi-system disease (e.g. cystic fibrosis, cancer under current treatment)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): The active comparator arm consists of Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per current inhaled steroid dose plus oral montelukast
- 2 (Type: PLACEBO_COMPARATOR): The placebo comparator arm consists of Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid dose plus placebo for montelukast

Based on this trial design, predict the completion outcome and termination type (if applicable).